他汀类药物与乳腺癌预后的关系  

The Relationship between Statins and the Prognosis of Breast Cancer

作　　者：路娜 王淼舟[2] 

机构地区：[1]青海大学,青海 西宁 [2]青海大学附属医院乳腺疾病诊疗中心,青海 西宁

出　　处：《临床医学进展》2021年第8期3632-3637,共6页Advances in Clinical Medicine

摘　　要：他汀类药物是临床上主要应用于针对心血管疾病的降脂药物,近年来,越来越多的研究证实了他汀类降脂药的抗肿瘤作用。在乳腺癌领域,他汀类药物被认为可以降低乳腺癌患者复发风险,降低乳腺癌的死亡率。对于乳腺癌辅助内分泌治疗的患者来说,口服芳香化酶抑制剂导致部分患者血脂异常,从而增加心血管疾病的发生。他汀类药物不仅在降脂上作用显著,其改善乳腺癌患者预后作用意义重大。Statins are mainly used clinically as lipid-lowering drugs for cardiovascular diseases. In recent years, more and more studies have confirmed the anti-tumor effects of statins. In the field of breast cancer, statins are believed to reduce the risk of recurrence of breast cancer patients and reduce the mortality rate of breast cancer. For patients undergoing adjuvant endocrine therapy for breast cancer, oral aromatase inhibitors can cause dyslipidemia in some patients, thereby increasing the incidence of cardiovascular disease. Statins not only have a significant effect on lowering lipids, but also have great significance in improving the prognosis of breast cancer patients.

关 键 词：乳腺癌 他汀类药物 芳香化酶抑制剂 

分 类 号：R73[医药卫生—肿瘤]